The Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, conducted an inspection visit to several facilities in Jeddah, including the Authority's branch office in the Western Region. This visit aimed to monitor operational progress and ensure the effectiveness of services to safeguard product safety. It is part of a series of routine tours across the Kingdom of Saudi Arabia to enhance oversight of products under the SFDA's jurisdiction.

The Saudi Food and Drug Authority (SFDA) advises that ginseng (scientifically known as Panax Ginseng), used in alternative medicine as a general tonic to enhance energy levels and mitigate stress, should be used with caution. High-dose consumption may result in side effects such as insomnia and high blood pressure. Furthermore, pregnant and lactating women are advised to avoid ginseng due to a lack of safety data.

The Saudi Food and Drug Authority (SFDA) has achieved a landmark milestone by becoming the first organization in the Middle East to be elected to the Management Committee of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), joining seven international counterparts and eight representatives from global organizations.

H.E. Dr. Hisham S. Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), recently conducted an inspection tour of the Authority’s Eastern Province branch, visiting several affiliated facilities.

In June 2024, the Saudi Food and Drug Authority (SFDA) identified six pharmacies for failing to provide registered pharmaceutical preparations to the local market, report drug movements in the electronic tracking system, or inform the SFDA of expected shortages or interruptions in the supply of registered preparations.

The Saudi Food and Drug Authority (SFDA) seized 571 unlicensed facilities engaged in the manufacture and storage of food, medicines, and medical devices in the regions of Makkah and Madinah, referring the violating establishments to the competent authorities for legal action.

The SFDA explained that it conducted 3,676 inspection visits to the facilities under its supervision during intensive supervisory tours as part of its role during the Hajj season, ensuring the safety of food, medicines, and medical products.

The Saudi Food and Drug Authority (SFDA) detected 187 violating facilities and 277 types of products during 1,959 monitoring and inspection tours conducted across all regions of the Kingdom in May 2024.

The third meeting of the Heads of National Medicines Regulatory Authorities (NMRAs) of the Organization of Islamic Cooperation (OIC) Member States concluded today. Held in Riyadh from December 17-18, the meeting was chaired by H.E. Dr. Hisham S. Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA).

The Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA), hosted the third meeting of the Heads of National Medicines Regulatory Authorities (NMRAs) of the Organization of Islamic Cooperation (OIC) Member States today, December 17-18, in Riyadh. The two-day event focused on the theme "Advancing Medicine Regulation and R&D Ecosystems: Pathways to Regulatory Maturity."